Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Bronchial Alveolar Carcinoma
NCT00003494Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Mar 1996
- Primary completion
- May 2002
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in bronchioloalveolar carcinoma (BAC), sponsored by Burzynski Research Institute. Primary endpoint: Objective Response to Therapy. Started Mar 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
bronchioloalveolar carcinoma (BAC)
Beyond the preview
Go deeper on NCT00003494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003494.